Innate Pharma vs TScan Therapeutics
IPHA and TCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IPHA and TCRX compare
TScan Therapeutics grew revenue faster over the last twelve months (2.2% versus −55.2% for Innate Pharma).
TScan Therapeutics scores higher on the StockData Score (4 against 0 for Innate Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IPHA | TCRX |
|---|---|---|
| Size and price | ||
| Market cap | – | $10.2M |
| Share price | $1.33 | $0.151 |
| Change, 1 year | −26.9% | −86.3% |
| Change, 5 years | −72.3% | −98.3% |
| Beta (5Y) | 1.28 | 2.15 |
| Employees | 181 | 142 |
| StockData Score | ||
| Total score | 0 | 4 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 0 | 1 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 1.4× |
| P/B | – | 0.1× |
| FCF yield | – | −1157% |
| Fair value | – | $1.36 |
| Margin of safety | – | 88.9% |
| Growth | ||
| Revenue growth (TTM) | −55.2% | 2.2% (better) |
| Revenue growth, 5Y average | −33.6% | 56.9% (better) |
| Profitability | ||
| Operating margin | −600% (better) | −1695% |
| Net margin | – | −1655% |
| FCF margin | −587% (better) | −1666% |
| Return on equity | – | −95.8% |
| Financial health | ||
| Debt / equity | – | 0.47 |
| Interest coverage | −17.3× (better) | −43.2× |
| Current ratio | 0.60 | 3.37 (better) |
| Altman Z-score | – | −6.31 |
| Piotroski F-score | – | 2 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 0.21% | 53.5% |
| Held by insiders | 16.2% | 32.8% |
| Insider net buying, 12 months | – | $146K |
| Short interest, % of float | – | 4.4% |
Go deeper
- IPHA stock overview
- IPHA income statement
- IPHA valuation and score
- TCRX stock overview
- TCRX income statement
- TCRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.